Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 142-150

  Lehmann, Brian D ^a   Pietenpol, Jennifer A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

AR; basal like; EGFR; FGFR; genomic instability; INPP4B; LDHB; PHGDH; PIK3CA; PTEN; subtypes; therapy; TNBCtype; TP53; triple negative breast cancer; VEGFR; WEE1

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ANDROGEN RECEPTOR; ANTHRACYCLINE; BEVACIZUMAB; BICALUTAMIDE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GEMCITABINE; GROWTH FACTOR RECEPTOR; INIPARIB; INOSITOL POLYPHOSPHATE 4 PHOSPHATASE TYPE II; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN P53; RAD51 PROTEIN; SUNITINIB; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ADD ON THERAPY; ADJUVANT THERAPY; ANGIOGENESIS; BASAL CELL; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL VIABILITY; DRUG EFFICACY; DRUG TOLERABILITY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; META ANALYSIS (TOPIC); MONOTHERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

AR; BASAL-LIKE; EGFR; FGFR; GENOMIC INSTABILITY; INPP4B; LDHB; PHGDH; PIK3CA; PTEN; SUBTYPES; THERAPY; TNBCTYPE; TP53; TRIPLE-NEGATIVE BREAST CANCER; VEGFR; WEE1;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PHENOTYPE; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890283025     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4280     Document Type: Review

References (65)

1. Bastien RR, Rodríguez-Lescure Á, Ebbert MT, et al., PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genom 2012; 5 (1): 44.
2. Dent R, Trudeau M, Pritchard KI, et al., Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13 (15, pt 1): 4429-4434.
3. Kreike B, van Kouwenhove M, Horlings H, et al., Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9 (5): R65.
4. Carey LA, Dees EC, Sawyer L, et al., The triple-negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13 (8): 2329-2334.
5. Liedtke C, Mazouni C, Hess KR, et al., Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26 (8): 1275-1281.
6. Lehmann BD, Bauer JA, Chen X, et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121 (7): 2750-2767.
7. Criscitiello C, Azim HA, Schouten PC, et al., Understanding the biology of triple-negative breast cancer. Ann Oncol 2012; 23 (suppl 6): vi, 13-18.
8. Gao J, Aksoy BA, Dogrusoz U, et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6 (269): pl1.
9. Cerami E, Gao J, Dogrusoz U, et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2 (5): 401-404.
10. Shah SP, Roth A, Goya R, et al., The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486 (7403): 395-399.
11. Nagle RB, Böcker W, Davis JR, et al., Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 1986; 34 (7): 869-881.
12. Perou CM, Sørlie T, Eisen MB, et al., Molecular portraits of human breast tumours. Nature 2000; 406 (6797): 747-752.
13. Gusterson BA, Ross DT, Heath VJ, Stein T,. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 2005; 7 (4): 143-148.
14. Sorlie T, Perou CM, Tibshirani R, et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98 (19): 10869-10874.
15. Reis-Filho JS, Tutt ANJ,. Triple-negative tumours: a critical review. Histopathology 2008; 52 (1): 108-118.
16. Rody AA, Karn TT, Liedtke CC, et al., A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011; 13 (5): R97.
17. Desmedt C, Haibe-Kains B, Wirapati P, et al., Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14 (16): 5158-5165.
18. Teschendorff AE, Caldas C,. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res 2008; 10 (4): R73.
19. Chen X, Li J, Gray WH, et al., TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer Inform 2012; 11: 147-156.
20. Prat AA, Parker JSJ, Karginova OO, et al., Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12 (5): R68.
21. Masuda H, Baggerly KA, Wang Y, et al., Differential response to neoadjuvant chemotherapy among seven triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19 (19): 5533-5540.
22. Livasy CA, Karaca G, Nanda R, et al., Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19 (2): 264-271.
23. Lee KH, Han SW, Hwang PG, et al., Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. Jpn J Clin Oncol 2006; 36 (6): 344-350.
24. Carey LA, Rugo HS, Marcom PK, et al., TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30 (21): 2615-2623.
25. Baselga J, Gõmez P, Greil R, et al., Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31 (20): 2586-2592.
26. Baselga J, Norton L, Masui H, et al., Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85 (16): 1327-1333.
27. Kranz A, Mattfeldt T, Waltenberger J,. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 1999; 84 (3): 293-298.
28. Burstein HJ, Elias AD, Rugo HS, et al., Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26 (11): 1810-1816.
29. Minckwitz von GG, Eidtmann HH, Rezai MM, et al., Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366 (4): 299-309.
30. Crown JP, Diéras V, Staroslawska E, et al., Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013; 31 (23): 2870-2878.
31. Cameron D, Brown J, Dent R, et al., Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase III trial. Lancet Oncol 2013; 14 (10): 933-942.
32. Turner N, Lambros MB, Horlings HM, et al., Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29 (14): 2013-2023.
33. Courjal F, Cuny M, Simony-Lafontaine J, et al., Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 1997; 57 (19): 4360-4367: http://eutils.ncbi. nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=9331099&retmode= ref&cmd=prlinks
34. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490 (7418): 61-70.
35. Birkbak NJ, Wang ZC, Kim J-Y, et al., Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012; 2 (4): 366-375.
36. Sharpe R, Pearson A, Herrera-Abreu MT, et al., FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011; 17 (16): 5275-5286.
37. Graeser M, McCarthy A, Lord CJ, et al., A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010; 16 (24): 6159-6168.
38. Abkevich VV, Timms KMK, Hennessy BTB, et al., Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012; 107 (10): 1776-1782.
39. Bhattacharyya AA, Ear USU, Koller BHB, et al., The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275 (31): 23899-23903.
40. Venkitaraman AR,. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108 (2): 171-182.
41. Evers BB, Drost RR, Schut EE, et al., Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14 (12): 3916-3925.
42. Gonzalez-Angulo AM, Timms KM, Liu S, et al., Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17 (5): 1082-1089.
43. Silver DP, Richardson AL, Eklund AC, et al., Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28 (7): 1145-1153.
44. Von Minckwitz G, Schneeweiss A, Salat C, et al., A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol 2013; 31 (suppl): abstr 1004.
45. Farmer H, McCabe N, Lord CJ, et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 (7035): 917-921.
46. Gelmon KA, Tischkowitz M, Mackay H, et al., Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12 (9): 852-861.
47. Kummar SS, Ji JJ, Morgan RR, et al., A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012; 18 (6): 1726-1734.
48. O'Shaughnessy J, Osborne C, Pippen JE, et al., Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364 (3): 205-214.
49. Telli ML, Jensen KC, Kurian AW, et al., PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer. J Clin Oncol 2013; 31: abstr 1003.
50. Liu XX, Shi YY, Maag DXD, et al., Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012; 18 (2): 510-523.
51. Wang ZC, Birkbak NJ, Culhane AC, et al., Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012; 18 (20): 5806-5815.
52. Marty BB, Maire VV, Gravier EE, et al., Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008; 10 (6): R101.
53. Gewinner C, Wang ZC, Richardson A, et al., Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009; 16 (2): 115-125.
54. Fedele CG, Ooms LM, Ho M, et al., Inositol poly phosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA 2010; 107 (51): 22231-22236.
55. Banerji SS, Cibulskis KK, Rangel-Escareno CC, et al., Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486 (7403): 405-409.
56. Lin J, Sampath D, Nannini MA, et al., Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 2013; 19 (7): 1760-1772.
57. Aarts M, Sharpe R, Garcia-Murillas I, et al., Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012; 2 (6): 524-539.
58. Leijen S, Schellens JH, Shapiro G, et al., A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol 2010; 28 (15, suppl): 3067.
59. Lehmann BD, Pietenpol JA,. Targeting mutant p53 in human tumors. J Clin Oncol 2012; 30 (29): 3648-3650.
60. Lang GAG, Iwakuma TT, Suh Y-AY, et al., Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119 (6): 861-872.
61. Olive KPK, Tuveson DAD, Ruhe ZCZ, et al., Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119 (6): 847-860.
62. Gucalp A, Traina TA,. Triple-negative breast cancer: role of the androgen receptor. Cancer J 2010; 16 (1): 62-65.
63. Farmer P, Bonnefoi H, Becette V, et al., Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24 (29): 4660-4671.
64. Gucalp A, Tolaney S, Isakoff SJ, et al., Phase II trial of bicalutamide in patients with androgen receptor positive, hormone receptor negative metastatic breast cancer. Clin Cancer Res 2013; 19 (19): 5505-5512.
65. Loibl S, Muller BM, Minckwitz von G, et al., Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011; 130 (2): 477-487.